INTENT TO SOLE SOURCE Wolters Kluwer VitalLaw Platform Subscription FDA – 75F40126Q00066

The FDA's Office of Acquisition and Grant Services issued an Intent to Sole Source notice on February 13, 2026, for the renewal of a subscription to the Wolters Kluwer VitalLaw Platform. The contracting activity is being conducted under solicitation number FDA-75F40126Q00066 and is classified under the IT and Telecom - Platform As A Service category (PSC: DH10). The FDA's Office of the Chief Counsel intends to award a Firm Fixed Price Purchase Order to CCH Incorporated for continued access to legal research and content services. This special notice serves as a pre-award notification to allow interested parties an opportunity to submit capability statements before the sole source award is finalized. The response deadline for interested parties is February 24, 2026, at 1:00 PM EST.

The FDA seeks to maintain subscription access to four specialized legal libraries through the VitalLaw platform: Administrative Law Treatise, Food, Drug & Cosmetic Law Library, Generic & Innovator Drugs, and Medical Devices Library. The contract will have a one-year base period followed by four optional one-year periods. The FDA justifies the sole source award under FAR 6.302-1, citing that CCH Incorporated is the only responsible source capable of providing the proprietary legal content, particularly the Food, Drug, and Cosmetic Law Reporter and Medical Devices Reporter. The subscription will provide unlimited user IDs for FDA attorneys and staff with 24/7 access, customer support, and on-demand training services. Interested parties may submit capability statements to Terina Hicks at terina.hicks@fda.hhs.gov, and the government reserves the right not to compete the requirement based on responses received.